Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Wins Best Contract Research Organisation at the Annual Scrip Awards 2017


ICON recognised for partnership capabilities and innovation in
patient recruitment

ICON plc, (NASDAQ:ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, has won Best Contract Research Organisation –
Full-Service Providers at the 2017 Scrip Awards, which took place in
London on 29 November.

The Scrip Awards honour the pharmaceutical industry's highest achieving
individuals and organisations, with the Best Contract Research
Organisation acknowledging the critical role that CROs play in drug
development. ICON was selected by a panel of senior industry experts
from around the world, as the best CRO according to the following

  • Quality of services and relationships with clients
  • Innovations in patient recruitment strategy
  • Capabilities and strengths offered
  • Delivery of results that exceed sponsor expectations
  • Improvement in performance
  • Progress towards streamlining data collection and reporting

"We are very proud to be recognised as the industry's best," commented
Dr. Steve Cutler, Chief Executive Officer, ICON plc. "Through
innovations in patient recruitment and a strong commitment to
accountability and delivery, we have exceeded customer expectations in a
wide range of studies and have beaten industry medians in critical study
performance metrics. Building collaborative teams that work in
partnership with our customers is a key focus at ICON and it is very
pleasing to see the efforts of our employees being rewarded."

ICON continues to drive efficiency in drug development, by
revolutionising the paradigm for site and patient identification, and
improving site relationships, performance and engagement. Through an
owned network of 52 sites and EMR partnerships with IBM
and TriNetX,
ICON can help sponsors to more easily identify suitable patients.
Furthermore, ICON's FIRECREST
digital solutions improve the clinical trial experience for sites,
patients and study staff resulting in reduced time, cost and better
quality data.

ICON's Best CRO Award from Scrip follows a range of other industry
awards throughout 2017, including Best
Vaccines CRO
, PharmaTimes
Best Partnership in Clinical Research
and PharmaTimes Clinical
Researcher of the Year. A full list of ICON's industry awards can be
viewed at

About ICON plc

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees.

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!